Frontotemporal dementia patients with extrapyramidal symptoms have brainstem atrophy and reduced metabolism in certain areas of the brain significantly more often than patients without extrapyramidal ...
May 23, 2012 (Philadelphia, Pennsylvania) — The antipsychotic cariprazine (Forest Laboratories Inc, Gedeon Richter Plc) is effective for treating mania in bipolar disorder (BD), new research suggests.
Depression with anxiety disorder started in summer of 2004. From 28/7/2004 to 22/11/2004 (4 months) the patient was taking Citalopram 20 mg per day and Alprazolam 0.5 mg three times per day. On ...
Aripiprazole (Abilify, Otsuka Pharmaceuticals Europe) is an antipsychotic with partial dopamine D2 and D3 agonistic properties. It has a UK marketing authorisation 'for the treatment up to 12 weeks of ...
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd., announced today that the U.S. Food and Drug Administration (FDA) has approved ...
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from the pivotal ...
The extended-release delivery coupled with the 351mg dose allows for single-dose initiation. Erzofri ® (paliperidone palmitate) extended-release injectable suspension is now available for the ...
Erzofri is an atypical antipsychotic that is administered once a month as an intramuscular injection. The Food and Drug Administration (FDA) has approved Erzofri ® (paliperidone palmitate) ...
Aripiprazole (Abilify, Otsuka Pharmaceuticals Europe) is an antipsychotic with partial dopamine D2 and D3 agonistic properties. It has a UK marketing authorisation 'for the treatment up to 12 weeks of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback